Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
NCT05201404 · LIVERATION Phase 3Recruiting
- Lead sponsor
- Can-Fite BioPharma (Industry)
- Enrollment
- 471 (estimated)
- Start date
- 15 Mar 2023
- Primary completion
- Feb 2026 (estimated)
- Study completion
- 1 Oct 2026
- Last update posted
- 29 Apr 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Namodenoson Drug
- Placebo Drug
Conditions and primary outcome
- Hepatocellular Carcinoma
- Cirrhosis
Primary outcome
Overall Survival (OS) (From the time of randomization until the date of death from any cause, assessed up to 60 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05201404.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05201404 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.